Paul B Mullan

List of Publications by Year
in descending order

23 papers	929 citations	623574 14 h-index	642610 23 g-index
23 all docs	23 docs citations	23 times ranked	2158 citing authors

#	Article	IF	Citations
1	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw199.	3.0	338
2	Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt335.	3.0	91
3	The gene regulatory network for breast cancer: integrated regulatory landscape of cancer hallmarks. Frontiers in Genetics, 2014, 5, 15.	1.1	74
4	The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology, 2014, 65, 340-352.	1.6	59
5	The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-Î³-mediated apoptosis. Oncogene, 2005, 24, 5492-5501.	2.6	53
6	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, 2018, 2018, 1-14.	0.6	44
7	NF-Î²B is a critical mediator of BRCA1-induced chemoresistance. Oncogene, 2014, 33, 713-723.	2.6	41
8	A BRCA1 deficient, NFÎ²B driven immune signal predicts good outcome in triple negative breast cancer. Oncotarget, 2016, 7, 19884-19896.	0.8	30
9	Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. Modern Pathology, 2015, 28, 428-436.	2.9	27
10	BRCA1â€"A good predictive marker of drug sensitivity in breast cancer treatment?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 205-216.	3.3	25
11	Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. Oncotarget, 2018, 9, 4722-4736.	0.8	22
12	Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs). Oncotarget, 2016, 7, 55458-55472.	0.8	19
13	PICan: An integromics framework for dynamic cancer biomarker discovery. Molecular Oncology, 2015, 9, 1234-1240.	2.1	15
14	The identification of a novel role for BRCA1 in regulating RNA polymerase I transcription. Oncotarget, 2016, 7, 68097-68110.	0.8	15
15	Development of a potent and selective cell penetrant Legumain inhibitor. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5642-5645.	1.0	14
16	Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt. Oncotarget, 2019, 10, 4630-4639.	0.8	12
17	NUP98 â€" a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer. BMC Cancer, 2019, 19, 236.	1.1	11
18	P3 SAR exploration of biphenyl carbamate based Legumain inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2521-2524.	1.0	9

#	Article	IF	Citations
19	Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. Oncotarget, 2015, 6, 43244-43254.	0.8	8
20	Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer. Journal of Oncology, 2020, 2020, 1-10.	0.6	7
21	Flat SAR of P3-methylsulphonamide based small molecule legumain inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 413-416.	1.0	6
22	Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090604.	1.4	5
23	Identification and SAR exploration of a novel series of Legumain inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1546-1548.	1.0	4